kidneyintelX.dkd: An Innovation in Precision Medicine for Diabetic Kidney Disease - PubMed (original) (raw)

. 2025 Dec 1;36(12):2495-2497.

doi: 10.1681/ASN.0000000644. Epub 2025 Jan 30.

Affiliations

kidneyintelX.dkd: An Innovation in Precision Medicine for Diabetic Kidney Disease

Steven G Coca et al. J Am Soc Nephrol. 2025.

No abstract available

Keywords: CKD; diabetes mellitus; prediction modeling; progression.

PubMed Disclaimer

Conflict of interest statement

Disclosure forms, as provided by each author, are available with the online version of the article at http://links.lww.com/JSN/F50.

References

    1. Levin A Ahmed SB Carrero JJ, et al. Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns. Kidney Int. 2024;105(4):684–701. doi: 10.1016/j.kint.2023.10.016 - DOI - PubMed
    1. Waikar SS Rebholz CM Zheng Z, et al. Biological variability of estimated GFR and albuminuria in CKD. Am J Kidney Dis. 2018;72(4):538–546. doi: 10.1053/j.ajkd.2018.04.023 - DOI - PMC - PubMed
    1. Tang S, Shao H, Ali MK, Zhang P. Recommended and prevalent use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in a national population-based sample. Ann Intern Med. 2023;176(4):582–583. doi: 10.7326/M22-3051 - DOI - PMC - PubMed
    1. Neuen BL, Tuttle KR, Vaduganathan M. Accelerated risk-based implementation of guideline-directed medical therapy for type 2 diabetes and chronic kidney disease. Circulation. 2024;149(16):1238–1240. doi: 10.1161/CIRCULATIONAHA.123.068524 - DOI - PubMed
    1. Lafayette RA. Stop sitting on our RAASes: get moving with the most effective care for our patients. J Am Soc Nephrol. 2024;35(11):1610–1612. doi: 10.1681/ASN.0000000000000473 - DOI - PMC - PubMed